Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Insmed Inc. (INSM) Appoints New VP to Guide the Company through Research and Development

Insmed Inc. (Nasdaq: INSM) develops follow-on biologics for the competitive biopharmaceuticals market. To continue strengthening its position in the industry, the company relies on its proprietary protein platform and a seasoned management team. The company today announced Jim Miller, Ph.D., as vice president of Process Development, a role in which Dr. Miller will help develop the company’s follow-on biologics portfolio.

“We are excited to have Jim join our experienced team. His background is well suited to further accelerate progress on our follow-on biologics portfolio as we reach a critical stage in the development process of these product candidates,” Doug Farrar, senior vice president of Manufacturing Operations for Insmed stated in the press release.

Dr. Miller has more than 25 years of experience in biopharmaceutical product research and preclinical development. He previously served as co-founder and executive vice president of Product Development at Saronyx Inc.; and senior development, operations and research positions at both Reneneron Pharmaceuticals Inc. and Amgen.

The new vice president’s background in research and development is a good fit for Insmed’s goals to further develop its line of treatments to fight anemia, neutropenia and autoimmune diseases, as well as research in oncology.

“I am pleased to be joining the Insmed team, which has consistently demonstrated its advanced knowledge of biologics development, manufacturing capability and its skilled scientific and technical workforce,” Dr. Miller stated. “I am excited to be a part of the first U.S.-based biotechnology company to develop a comprehensive portfolio of follow-on biologics and look forward to working with the team to continue advancing these product candidates as rapidly as possible through the development process.”

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *